You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Inhaled nisin as an emergency intervention against antibiotic sensitive or resist

    SBC: AFG BIOSOLUTIONS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The deliberate release of Bacillus anthracis spores remains an imminent threat both in terms of bioterrorism and biowarfare. Individuals who inhale these spores are at extreme risk of infection and death from anthrax. C urrent prophylaxis and therapy in the event of B. anthracis spore inhalation fall into two categories. Vaccination to protect against future ex ...

    SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  2. Multiplex Lyme Disease Diagnostic

    SBC: AGAVE BIOSYSTEMS INC.            Topic: N/A

    DESCRIPTION (provided by investigator): Lyme disease, caused by the gram-negative spirochete Borrelia burgdorferi and transmitted by Ixodid tick species, is the leading vector-borne infectious disease in the United States, with a steady rise in the number of cases reported each year. The most common Lyme disease symptom, the classic bull's-eye rash (erythema migrans or EM rash) in endemic areas, ...

    SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  3. Lactoferrin Enhances Growth and Reduces Nosocomial Infection in Preterm Infants

    SBC: AGENNIX, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): This project aims to develop talactoferrin (TLF, recombinant human lactoferrin) as a therapeutic agent to treat prematurely born neonates. The treatment will be given orally shortly after birth to prevent nosocomial inf ections (NIs) due to abnormal bacterial invasion of neonatal intestinal epithelia and consequently to limit systemic bacteremia and necrotizing ...

    SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  4. Add-on module for ONCAD for diagnosing infiltrating lobular carcinoma

    SBC: Alan Penn & Associates Inc            Topic: N/A

    DESCRIPTION (provided by applicant): The specific aim of this study is to develop an add-on module for the ONCAD breast MRI CAD system that will provide radiologists with additional assistance when they have suspicion of the presence of infiltrating lobula r carcinoma (ILC). The proposed research will investigate the possibility of developing, training and evaluating an ILC- specific algorithm tha ...

    SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  5. New Reagents for Synthesizing Nuclease-resistant siRNA

    SBC: AM BIOTECHNOLOGIES, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): The siRNA molecule needs better protection from nuclease degradation before it can be effectively used as a therapeutic. AM Biotechnologies (AM) will address this critical issue by developing ribonucleoside thiophospho ramidite (ABz, CBz, GIbu and U) reagents that will enable synthesis of phosphorodithioate siRNA (PS2-siRNA). This synthesized PS2-siRNA will si ...

    SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  6. Novel RNA Markers for Detecting Colon Cancer Metastasis

    SBC: AMBION DIAGNOSTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Lymph node evaluation is an important prognostic factor in colorectal cancer (CRC) because accurate identification of lymph node metastases significantly influences survival. However, a 30% recurrence rate in patients w ith node-negative CRC clearly indicates that current staging methods are inadequate. The primary form of treatment for all stages of colon canc ...

    SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  7. MicroRNA biomarkers for early detection of prostate cancer

    SBC: AMBION DIAGNOSTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Prostate cancer (PrCa) is the most commonly diagnosed cancer in American men, with over 218,000 new cases diagnosed each year. It is second only to lung cancer in cancer mortality among men, and approximately 1 man in 5 will be diagnosed during his lifetime. When it is detected early, PrCa can be cured. In contrast, patients with metastatic prostate cancer hav ...

    SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  8. RNA Amplification for Diagnostic Microarrays

    SBC: AMBION DIAGNOSTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The overall goal of this proposal is to develop and implement an integrated suite of technologies for enabling microarray-based diagnostic assays and the cGMP manufacturing processes and procedures necessary to manufact ure these products. Microarrays have found widespread use in biology and medicine as important tools for evaluating gene expression and genomic ...

    SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  9. Streamlined labeling of degraded RNA for expression arrays

    SBC: AMBION DIAGNOSTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): This is a proposal to develop a cGMP-manufactured RNA labeling kit suitable for clinical diagnostic assays and research applications that require multiplex RNA detection. The kit's target preparation technology will en able accurate and reproducible profiling of total RNA, including both microRNA (miRNA) and mRNA transcripts when combined with compatible micro ...

    SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  10. Generation of a Modified DT_IL3 Fusion Toxin

    SBC: ANJIN GROUP, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): A number of protein fusion toxins, composed of the diphtheria toxin (DT) toxophore and a targeting ligand, have been assembled and tested in Phase I clinical trials for the treatment of leukemias. To date, the only FDA approved protein fusion toxin is ONTAK. ONTAK is a DT, interleukin-2 receptor-targeted fusion toxin used to treat persistent or recurrent, cuta ...

    SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government